Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APRENASDAQ:CDTNASDAQ:CINGNASDAQ:FLGC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPREAprea Therapeutics$1.95-4.7%$2.99$1.94▼$6.70$10.69M0.8219,162 shs33,138 shsCDTConduit Pharmaceuticals$0.75-3.5%$1.77$0.73▼$360.00$2.75M2.293.93 million shs2.80 million shsCINGCingulate$4.27-0.8%$4.27$1.80▼$20.83$13.73M-0.831.06 million shs94,674 shsFLGCFlora Growth$0.59-1.8%$0.77$0.59▼$2.75$11.55M1.99318,934 shs72,500 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPREAprea Therapeutics-2.39%-9.73%-19.37%-37.99%-69.51%CDTConduit Pharmaceuticals-12.25%-11.10%-34.92%-88.62%-99.79%CINGCingulate-1.15%+9.14%+4.37%-12.78%+290.91%FLGCFlora Growth-6.92%-7.89%-19.81%-41.26%-73.81%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPREAprea Therapeutics2.8305 of 5 stars3.53.00.00.03.00.81.3CDTConduit Pharmaceuticals0.3027 of 5 stars0.02.00.00.01.91.70.0CINGCingulate3.2369 of 5 stars3.65.00.00.02.61.70.6FLGCFlora Growth3.1702 of 5 stars3.35.00.00.02.80.81.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPREAprea Therapeutics 3.00Buy$15.50696.92% UpsideCDTConduit Pharmaceuticals 4.00Strong BuyN/AN/ACINGCingulate 3.25Buy$16.00274.97% UpsideFLGCFlora Growth 2.67Moderate Buy$5.00741.75% UpsideCurrent Analyst Ratings BreakdownLatest CDT, FLGC, CING, and APRE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/25/2025APREAprea TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$11.003/6/2025CINGCingulateHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.001/30/2025CINGCingulateHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$8.00 ➝ $20.001/15/2025APREAprea TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.001/10/2025CINGCingulateRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy1/10/2025CINGCingulateRoth MkmSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$12.00(Data available from 4/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPREAprea Therapeutics$580K18.42N/AN/A$4.54 per share0.43CDTConduit PharmaceuticalsN/AN/AN/AN/A($0.62) per shareN/ACINGCingulateN/AN/AN/AN/A($70.63) per shareN/AFLGCFlora Growth$59.51M0.19N/AN/A$0.78 per share0.76Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPREAprea Therapeutics-$14.29M-$2.38N/AN/AN/A-1,029.50%-57.86%-47.94%5/13/2025 (Estimated)CDTConduit Pharmaceuticals-$540K-$39.33N/A∞N/AN/AN/A-328.67%4/15/2025 (Estimated)CINGCingulate-$23.53M-$14.64N/AN/AN/AN/A-570.20%-236.15%4/7/2025 (Estimated)FLGCFlora Growth-$57.04M-$1.32N/AN/AN/A-30.99%-268.17%-57.51%5/13/2025 (Estimated)Latest CDT, FLGC, CING, and APRE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/7/2025N/ACINGCingulate-$1.48N/AN/AN/AN/AN/A3/28/2025Q4 2024CDTConduit PharmaceuticalsN/A-$20.33N/A-$20.33N/AN/A3/25/2025Q4 2024APREAprea Therapeutics-$0.69-$0.49+$0.20-$0.49$0.15 million$0.21 million3/24/2025Q4 2024FLGCFlora Growth-$0.11-$0.42-$0.31-$0.45$13.55 million$13.33 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPREAprea TherapeuticsN/AN/AN/AN/AN/ACDTConduit PharmaceuticalsN/AN/AN/AN/AN/ACINGCingulateN/AN/AN/AN/AN/AFLGCFlora GrowthN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPREAprea TherapeuticsN/A7.287.28CDTConduit PharmaceuticalsN/A0.120.12CINGCingulateN/A7.357.35FLGCFlora Growth0.431.020.64Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPREAprea Therapeutics34.19%CDTConduit Pharmaceuticals3.29%CINGCingulate41.31%FLGCFlora Growth36.01%Insider OwnershipCompanyInsider OwnershipAPREAprea Therapeutics12.80%CDTConduit Pharmaceuticals30.93%CINGCingulate17.06%FLGCFlora Growth12.99%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPREAprea Therapeutics75.49 million4.74 millionNo DataCDTConduit Pharmaceuticals33.64 million710,000Not OptionableCINGCingulate203.21 million2.66 millionNot OptionableFLGCFlora Growth28019.44 million12.55 millionNot OptionableCDT, FLGC, CING, and APRE HeadlinesRecent News About These CompaniesFlora Growth sees revenue drop across all businesses in 2024March 25, 2025 | greenmarketreport.comFlora Growth Corp. Reports 2024 Financial ResultsMarch 24, 2025 | newsfilecorp.comFlora Growth files to sell 3.21M common shares for holdersFebruary 24, 2025 | markets.businessinsider.comFlora Growth hires innovation leader for Vessel brandFebruary 11, 2025 | msn.comFlora Announces Appointment of Patrick Moloney as Head of Product Development for VesselFebruary 11, 2025 | newsfilecorp.comFlora Growth stock hits 52-week low at $0.74 amid market challengesJanuary 29, 2025 | msn.comClifford Starke's Holdings in Flora Growth Corp.December 17, 2024 | newsfilecorp.comWhat’s Causing Flora Growth Corp (FLGC) Stock’s 18.18% Jump Over the Last Six Months?December 17, 2024 | bovnews.comFlora Growth Raises $3.6 Million in Stock OfferingDecember 16, 2024 | tipranks.comFlora Growth Corp. Announces Closing of $3.6 Million Registered Direct OfferingDecember 16, 2024 | newsfilecorp.comFlora Growth Corp. Announces Pricing of $3.6 Million Registered Direct OfferingDecember 13, 2024 | investing.comFlora Growth Corp. Announces Pricing of $3.6 Million Registered Direct OfferingDecember 13, 2024 | newsfilecorp.comFlora Growth Ends Agreement with Aegis CapitalDecember 12, 2024 | markets.businessinsider.comFlora Growth Applauds Launch of German Cannabis Pilot ProgramsDecember 12, 2024 | newsfilecorp.comFlora Growth Restructures Board with New AppointmentsDecember 11, 2024 | tipranks.comFlora Growth's Peak USA Celebrates the Launch of THC-Infused Beverage Brand, Melo, in Total Wines & MoreDecember 11, 2024 | newsfilecorp.comFlora Growth Corp.: Flora Growth Appoints Sammy Dorf, Verano Co-Founder, as Executive ChairmanDecember 10, 2024 | finanznachrichten.deFlora Growth Appoints Sammy Dorf, Verano Co-Founder, as Executive ChairmanDecember 10, 2024 | newsfilecorp.comCannabis Co. Flora Growth Wants To Allow Customers To Pay With Bitcoin As It Shatters $100K MarkDecember 5, 2024 | benzinga.comFlora to Launch Bitcoin Payment IntegrationDecember 4, 2024 | newsfilecorp.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesIs BigBear.ai's 25% Plunge a False Alarm or Fire Sale?By Jeffrey Neal Johnson | March 7, 2025View Is BigBear.ai's 25% Plunge a False Alarm or Fire Sale?4 EV Stocks Facing Uncertainty—Which Ones Will Survive?By Thomas Hughes | March 7, 2025View 4 EV Stocks Facing Uncertainty—Which Ones Will Survive?Could Palantir’s R1 Deal Be the Catalyst for a Stock Surge?By Chris Markoch | March 21, 2025View Could Palantir’s R1 Deal Be the Catalyst for a Stock Surge?D-Wave Quantum Stock Jumps on "Quantum Supremacy" NewsBy Chris Markoch | March 14, 2025View D-Wave Quantum Stock Jumps on "Quantum Supremacy" NewsAbbVie Stock Boosts Portfolios With Entry Into Weight Loss MarketBy Chris Markoch | March 23, 2025View AbbVie Stock Boosts Portfolios With Entry Into Weight Loss MarketCDT, FLGC, CING, and APRE Company DescriptionsAprea Therapeutics NASDAQ:APRE$1.94 -0.10 (-4.66%) As of 02:32 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.Conduit Pharmaceuticals NASDAQ:CDT$0.77 -0.01 (-1.54%) As of 02:33 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.Cingulate NASDAQ:CING$4.27 -0.03 (-0.79%) As of 02:32 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.Flora Growth NASDAQ:FLGC$0.59 -0.01 (-1.82%) As of 02:11 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Flora Growth Corp., together with its subsidiaries, engages in the growth, cultivation, and development of medicinal cannabis and medicinal cannabis derivative products worldwide. It operates through three segments: House of Brands, Commercial and Wholesale, and Pharmaceuticals. The company cultivates, processes, and supplies medicinal-grade cannabis flower, and cannabis derived medical and wellness products. It also offers food and beverage, nutraceuticals, cannabis accessories and technology, personal care, and wellness; cannabidiol (CBD) derived products, such as gummies, topicals, tinctures, and vape products; cannabis consumption accessories, personal storage, and travel accessories for the vape and dry herbs. In addition, the company manufactures and distributes pharmaceutical goods and medical cannabis products to treat a variety of health indications, including drugs related to cancer therapies, attention-deficit/hyperactivity disorder, multiple sclerosis, and anti-depressants. The company sells its products under the JustCBD, Vessel, and Phatebo brands. Flora Growth Corp. was incorporated in 2019 and is based in Fort Lauderdale, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas D-Wave: Multiple Use Cases Emerge Following Quantum Supremacy Amazon Falls Back to a Key Support Line: Here's How to Play It Berkshire Hathaway Gains Defy Stock Market Slump Tech Sell-Off Makes Microsoft Stock Look Like a Steal Palantir Stock Builds Momentum on New Partnership Amprius Market Gets Amped Up on Growth Outlook 3 Buyable Stocks With Solid Bottoms Ready to Rebound Game-Changing News for Advanced Micro Devices Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
